Difference between revisions of "Anaplastic large cell lymphoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 9: Line 9:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 +
 +
=Untreated=
 +
 +
==CHOEP {{#subobject:c516ab|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
CHOEP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone
 +
 +
Synonyms: CHOPE, VACOP
 +
 +
Structured Concept: [http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary==NCI%20Thesaurus&version==12.09d&code==C9702&key==1863263010&b==1&n==null C9702] (NCI-T), [http://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary==NCI%20MetaThesaurus&code==C0212922 C0212922](NCI-MT/UMLS)
 +
 +
===Example orders===
 +
*[[Example orders for CHOEP in lymphoma]]
 +
 +
===Regimen {{#subobject:f61648|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 +
|[[Levels_of_Evidence#Toxicity|'''Toxicity''']]
 +
|-
 +
|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
 +
|<span
 +
style="background:#00CD00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III, >20 patients in this arm</span>
 +
|CHOP-21;CHOP-14
 +
|Not reported by subgroup
 +
|Not reported by subgroup
 +
|}
 +
 +
''This regimen was used in 20 ALCL patients (CHOEP-21) and 16 ALCL patients (CHOEP-14) in the NHL-B1 trial. The authors did not report a subgroup analysis for this minority population.''
 +
 +
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1
 +
*[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV once on day 1
 +
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
 +
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
 +
*[[Etoposide (Vepesid)]] 100 mg/m2 IV once per day on days 1 to 3
 +
*Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 36 Gy radiation therapy and to extranodal sites of disease when possible
 +
 +
Supportive medications:
 +
*For 14-day cycles: [[Filgrastim (Neupogen)]] 300 mcg (for patients <75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
 +
*[[Filgrastim (Neupogen)]] use for 21-day cycles is by discretion of ordering physician
 +
 +
'''14 or 21-day cycles x 6 cycles''', next cycle to start as long as WBC is >2.5 and platelets >80
 +
*CHOEP-14 uses 14-day cycles; CHOEP-21 uses 21-day cycles
 +
 +
===References===
 +
# Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://bloodjournal.hematologylibrary.org/content/104/3/626.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/14982884 PubMed]
 +
 +
==CHOP {{#subobject:4ca454|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
 +
 +
Synonyms: CHOP-21, ACOP, CAVP, COPA, VACP, VCAP
 +
 +
Structured Concept: [http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary==NCI%20Thesaurus&version==12.09d&code==C9549&key==1801231401&b==1&n==null C9549] (NCI-T), [http://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary==NCI%20MetaThesaurus&code==C0055598 C0055598] (NCI-MT/UMLS)
 +
 +
===Regimen {{#subobject:9e770b|Variant=1}}===
 +
{| border="1" style="text-align:center;" !align="left"
 +
|'''Study'''
 +
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 +
|'''Comparator'''
 +
|[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
 +
|[[Levels_of_Evidence#Toxicity|'''Toxicity''']]
 +
|-
 +
|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
 +
|<span
 +
style="background:#eeee00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase III, <20 patients in this arm</span>
 +
|CHOEP;CHOP-14
 +
|Not reported by subgroup
 +
|Not reported by subgroup
 +
|}
 +
 +
''This regimen was used in 14 ALCL patients in the NHL-B1 trial. The authors did not report a subgroup analysis for this minority population.''
 +
 +
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV once on day 1
 +
*[[Doxorubicin (Adriamycin)]] 50 mg/m2 IV once on day 1
 +
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
 +
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
 +
 +
Supportive medications:
 +
*At the discretion of ordering physician: [[Filgrastim (Neupogen)]] 300 mcg (for patients <75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
 +
 +
'''21-day cycle x 6 cycles'''
 +
 +
===References===
 +
# Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://bloodjournal.hematologylibrary.org/content/104/3/626.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/14982884 PubMed]
  
 
=Relapsed/refractory=
 
=Relapsed/refractory=

Revision as of 23:23, 28 March 2015

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

9 regimens on this page
12 variants on this page


Untreated

CHOEP

back to top

CHOEP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Etoposide, Prednisone

Synonyms: CHOPE, VACOP

Structured Concept: C9702 (NCI-T), C0212922(NCI-MT/UMLS)

Example orders

Regimen

Study Evidence Comparator Efficacy Toxicity
Pfreundschuh et al. 2004 (NHL-B1) Phase III, >20 patients in this arm CHOP-21;CHOP-14 Not reported by subgroup Not reported by subgroup

This regimen was used in 20 ALCL patients (CHOEP-21) and 16 ALCL patients (CHOEP-14) in the NHL-B1 trial. The authors did not report a subgroup analysis for this minority population.

Supportive medications:

  • For 14-day cycles: Filgrastim (Neupogen) 300 mcg (for patients <75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13
  • Filgrastim (Neupogen) use for 21-day cycles is by discretion of ordering physician

14 or 21-day cycles x 6 cycles, next cycle to start as long as WBC is >2.5 and platelets >80

  • CHOEP-14 uses 14-day cycles; CHOEP-21 uses 21-day cycles

References

  1. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. link to original article contains verified protocol PubMed

CHOP

back to top

CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone

Synonyms: CHOP-21, ACOP, CAVP, COPA, VACP, VCAP

Structured Concept: C9549 (NCI-T), C0055598 (NCI-MT/UMLS)

Regimen

Study Evidence Comparator Efficacy Toxicity
Pfreundschuh et al. 2004 (NHL-B1) Phase III, <20 patients in this arm CHOEP;CHOP-14 Not reported by subgroup Not reported by subgroup

This regimen was used in 14 ALCL patients in the NHL-B1 trial. The authors did not report a subgroup analysis for this minority population.

Supportive medications:

  • At the discretion of ordering physician: Filgrastim (Neupogen) 300 mcg (for patients <75 kg) or 480 mcg (for patients at least 75 kg) SC once per day on days 4 to 13

21-day cycle x 6 cycles

References

  1. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. link to original article contains verified protocol PubMed

Relapsed/refractory

Brentuximab vedotin (Adcetris)

back to top

Regimen, Pro et al. 2012

Phase II

3-week cycles up to 16 infusions

References

  1. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2190-6. Epub 2012 May 21. link to original article contains verified protocol PubMed
    1. Update: Abstract: Barbara Pro, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, Jeffrey Matous, MD, Radhakrishnan Ramchandern, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yinghui Wang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, BCOP and Andrei R. Shustov, MD. Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. ASH Annual Meeting 2014, Abstract 3095 link to abstract
  2. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013 Apr;98(4):611-4. Epub 2012 Oct 12. link to original article contains verified protocol PubMed

DHAP

back to top

DHAP: Dexamethasone, High-dose Ara-C (cytarabine), Platinol (cisplatin)

Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)

Phase III, <20 in this arm

21-day cycles x up to 3 cycles

References

  1. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. link to original article contains verified protocol PubMed

GDP

back to top

GDP: Gemcitabine, Dexamethasone, Platinol

Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)

Phase III, <20 in this arm

21-day cycles x up to 3 cycles

References

  1. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Anaplastic_large_cell_lymphoma&oldid=7729"